Enantioselective Copper‐Catalyzed Borylative Cyclization for the Synthesis of Quinazolinones by Dherbassy, Quentin et al.
Synthetic Methods
Enantioselective Copper-Catalyzed Borylative Cyclization for the
Synthesis of Quinazolinones
Quentin Dherbassy+, Srimanta Manna+, Chunling Shi, Watcharapon Prasitwatcharakorn,
Giacomo E. M. Crisenza, Gregory J. P. Perry, and David J. Procter*
Abstract: Quinazolinones are common substructures in mol-
ecules of medicinal importance. We report an enantioselective
copper-catalyzed borylative cyclization for the assembly of
privileged pyrroloquinazolinone motifs. The reaction proceeds
with high enantio- and diastereocontrol, and can deliver
products containing quaternary stereocenters. The utility of
the products is demonstrated through further manipulations.
Since the seminal reports of Hosomi[1] and Miyaura,[2] the
copper-catalyzed borylative functionalization of olefins has
emerged as a powerful method for stereocontrolled, complex
molecule construction.[3] Subsequent studies by Ito and
Sawamura,[4] and others,[5] have shown the utility of this
process in cyclization reactions. In particular, several groups
have used this strategy to construct valuable nitrogen-
containing heterocycles, such as indolines[6] and tetrahydro-
quinolines[7] (Scheme 1 A). In particular, Lautens has recently
described a copper-catalyzed stereoselective synthesis of
tetrahydroquinolines through a conjugate borylation/Man-
nich cyclization cascade.[7a] This process illustrates the poten-
tial of copper-catalyzed borylative cyclizations by: 1) forming
several stereocentres with high control; 2) incorporating
a boron group that can undergo further derivatization;
3) preparing an important class of nitrogen-containing het-
erocycle, in this case tetrahydroquinolines
Quinazolinones display important bioactivity.[8] In partic-
ular, pyrroloquinazolinones are common tricyclic motifs
found in drug molecules and natural products (Scheme 1B).
It is important to prepare these compounds enantioselectively
as quinazolinone enantiomers can display different bioactiv- ities.[9] Few current methods for the construction of quinazo-
linones are enantioselective,[8,10] and classical chiral resolution
and chiral pool synthesis are typically used, for example, to
access the enantiopure quinazolinones shown in Sche-
me 1B.[11] More recently, dihydroquinazolinones have been
prepared enantioselectively, typically from 2-aminobenz-
amide and aldehydes,[12] however, few enantioselective meth-
ods extend to the delivery of important pyrroloquinazolinone
scaffolds.[12h] Thus, new enantioselective approaches to pyrro-
loquinazolinone building blocks are needed for the synthesis
of known and as yet unknown bioactive targets.
We recognized that the enantioselective, copper-catalyzed
borylative cyclizations of substrates 1, involving intramolec-
ular addition of an organocopper intermediate to a C=N
electrophile,[3a] would constitute a valuable route to important
enantiomerically enriched pyrroloquinazolinone derivatives 2
(Scheme 1C). The resulting new process is highly enantio-
and diastereoselective, uses an inexpensive and non-toxic
catalyst, and exploits commercially available chiral ligands.
Scheme 1. Copper-catalyzed borylative cyclizations for the enantiose-
lective synthesis of N-heterocycles. A) Enantioselective approaches to
indolines and tetrahydroquinolines. B) Biologically active pyrroloquina-
zolinones. C) Enantioselective, copper-catalyzed borylative synthesis of
pyrroloquinazolinones.
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Furthermore, through subsequent derivatization, a variety of
potentially bioactive quinazolinones can be accessed.
We initially examined the borylative cyclization of
substrate 1a using CuCl and ligand Ph-BPE (L1, Table 1).
Although this ligand is commonly used in related copper-
catalyzed functionalizations, its use here proved ineffective
(Table 1, entry 1).[13] Fortunately, screening of other phos-
phine ligands (Table 1, entries 1–3) revealed both ligands L2
((S,S)-BDPP)[5f,g,i] and L3 ((R)-QuinoxP

)[4a,b, 5j] gave the
product 2a with encouraging enantiocontrol, albeit in mod-
erate yield. Additional phosphine and NHC ligands that have
been used in previous borylative functionalizations were
unsuccessful here (See Supporting Information).[14] We then
tested copper sources, bases and solvents (Table 1, entries 4–
6) and found Cu(MeCN)4PF6 with KOtBu in THF to be
optimal (Table 1, entry 6).
Interestingly, the addition of alcohols greatly influenced
the yield of the process (Table 1, entries 7 and 8), and 2a was
isolated in high yield, with excellent diastereo- and enantio-
control (Table 1, entry 8). The exact role of the alcohol in this
process remains unclear although it may facilitate catalyst
turnover by protonation of a copper–amide intermediate to
deliver product and regenerate a copper alkoxide.[15] Finally,
we tested the phenyl-substituted substrate 1b under our
optimized conditions (Table 1, entries 9 and 10). Although
ligand L3 was unsuccessful (Table 1, entry 9), the product 2b
was isolated in excellent yield and with very high diastereo-
and enantiocontrol when using ligand L2 (Table 1, entry 10).
Exposing substrate 1a to the latter conditions gave 2a in
substantially reduced yield (Table 1, entry 11).
We next explored the performance of various aryl-
substituted alkenes 1 b–1 k in the process (Scheme 2). In
almost all cases, borylative cyclization and construction of two
adjacent stereocentres—including a quaternary stereocen-
tre—proceeded efficiently to deliver pyrroloquinazolinones
2b–k with very good to excellent enantio- and diastereocon-
trol. For example, aryl groups bearing electron-rich substitu-
Table 1: Reaction optimization.[a]
Entry CuI Additive Ligand Yield dr er
1[b,c] CuCl – L1 10 83:17 64:26
2[b,c] CuCl – L2 51 >95:5 83:17
3[b,c] CuCl – L3 15 >95:5 79:21
4[b,d] CuCl – L3 10 >95:5 98:2
5[b,d,e] CuCl – L3 11 >95:5 95:5
6[b,d] Cu(MeCN)4PF6 – L3 35 >95:5 94:6
7[b,d] Cu(MeCN)4PF6 tBuOH L3 85 >95:5 84:16
8[b,d] Cu(MeCN)4PF6 iPrOH L3 82 >95:5 93:7
9[d,f ] Cu(MeCN)4PF6 iPrOH L3 87 80:20 58:42
10[d,f ] Cu(MeCN)4PF6 iPrOH L2 75 91:9 95:5
11[b,d] Cu(MeCN)4PF6 iPrOH L2 10 87:13 95:5
[a] For further details of the reaction optimization, see the Supporting
Information. Reaction conditions: 1 (0.2 mmol), B2pin2 (0.3 mmol), Cu
I
(10 mol%), ligand (12 mol%) in THF (2.0 mL) at 25 8C or 35 8C for 2–6 h
under nitrogen. The diastereoselectivity was determined by 1H NMR
analysis of the crude product mixtures. NMR yields are given. [b] With 1a
to give 2a. [c] Using NaOtBu (1.5 equiv). [d] Using KOtBu (1.5 equiv).
[e] Using dioxane (0.2 m). [f ] With 1b to give 2b.
Scheme 2. Scope with respect to the alkene. Reaction conditions:
1 (0.2 mmol), B2pin2 (0.3 mmol), [Cu(MeCN)4]PF6 (0.02 mmol), L2
(0.024 mmol), KOtBu (0.3 mmol in 1 m sol. THF), iPrOH (0.4 mmol)
in THF (1.7 mL) at 25 8C for 2–4 h under nitrogen. Yields of isolated
product are given. The diastereoselectivity was determined by 1H NMR
analysis of the crude products and er values were measured by HPLC
on chiral stationary phase. [a] Reaction run at 0 8C.
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ents at both meta- and para-positions gave products with very
high enantiocontrol (2c–2 f). Ortho-, meta- and para-halo-
genated aryl groups were also well tolerated (2g–2 i). Finally,
substrates bearing 2-napthyl and 2-thienyl groups gave the
desired products in high yield and with excellent enantiocon-
trol (2j, 2k). Additional substrates bearing heteroaryl groups
gave rise to unstable products (see Supporting Information).
The relative and absolute stereochemistry of the products was
determined by X-ray crystallographic analysis of a derivative
of 2e and 2 f.[16]
Various substitution on the aryl ring of the amidine
component of 1 was also tolerated (Scheme 3). For example,
the methyl- and fluorine-containing products 2 l and 2m were
obtained in high yield and with good to excellent enantio-
control. A thiophene-fused substrate was also compatible
with our standard conditions to give 2n with moderate
enantiocontrol. Building on our initial optimization (Table 1,
entry 8), we investigated the scope of the process with
additional monosubstituted alkene substrates 1o–r. The
product 2o was obtained in high yield and with excellent
diastereo- and enantiocontrol, thus suggesting that electron-
rich substrates are particularly well-suited to the process.
Halogenated substrates were also tested (2p–2r); borylative
cyclization proceeded well, albeit with lower enantiocontrol
for substrates 1q and 1r. The relative and absolute stereo-
chemistry of the products 2a, 2 o–2 r was assigned after X-ray
crystallographic analysis of a derivative of 2a.[16] Substrates
bearing substitution at the terminus of the alkene proved
unreactive (see Supporting Information).
The functionality in the dihydroquinalozinone products 2
presents opportunities for further transformations
(Scheme 4). The material (2b) for these transformations
was obtained by performing the enantioselective, borylative
cyclization on a gram-scale; essentially identical yield,
enantio- and diastereocontrol were observed (c.f. Table 1,
entry 10). We first converted product 2b into the trifluor-
oborate salt 3,[17] and the alcohol 4 ; the latter by oxidation
with H2O2. Methylation of the free amine group was also
carried out to give product 5. Finally, oxidation with DDQ
provided pyrroloquinazolinone product 6. It is noteworthy
that judicious choice of oxidant (H2O2 or DDQ) leads
selectively to either product 4 or 6. Products related to 6 are
common in medicine (Scheme 1B)[8] and our preparation of 6
represents a rare example of an enantioselective approach to
this class of compound.
We propose a tentative mechanism and stereochemical
model to rationalize the observed outcome of the cyclization
of aryl-substituted alkene substrates 1b (Scheme 5). Upon
formation of copper–boryl species II, enantioselective bor-
ocupration occurs across the double bond of the alkene to
give III. Our stereochemical model (Scheme 5B) suggests this
addition occurs with the smaller methylene group (R)
oriented towards the ligand P-aryl ring, rather than the
larger phenyl group on the substrate (TS-1a vs. TS-1b). Based
Scheme 3. Scope with respect to the amidine. Reaction conditions:
1 (0.2 mmol), B2pin2 (0.3 mmol), [Cu(MeCN)4]PF6 (0.02 mmol), L2
(0.024 mmol), KOtBu (0.3 mmol in 1 m sol. THF), iPrOH (0.4 mmol)
in THF (1.7 mL) at 25 8C or 30 8C for 2–4 h under nitrogen. Yields of
isolated product are given. The diastereoselectivity was determined by
1H NMR analysis of the crude products. ee values were measured by
HPLC on chiral stationary phase. [a] Reaction was run without iPrOH.
[b] B2pin2 (0.4 mmol), KOtBu (0.4 mmol in 1 m sol. THF) and (R)-
QuinoxP

L3 (0.024 mmol) were used. [c] (R,R)-()-2,3-bis(tert-Butyl-
methylphosphino)benzene (BenzP*; 0.024 mmol) was used as
a ligand.
Scheme 4. Gram-scale reaction and derivatizations of 2b. Conditions:
(i) see Scheme 2; (ii) KHF2 4 equiv, MeOH/H2O, 0 8C to RT; (iii) H2O2
2 equiv, K2CO3 2 equiv, THF, 20 8C; (iv) NaH 1.5 equiv, MeI 1.5 equiv,
THF, 0 8C to RT; (v) DDQ 1.5 equiv, CH2Cl2, 0 8C to RT.
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on previous reports, a favourable face-to-face interaction
between the phenyl group on the alkene of the substrate and
the P-aryl ring might further stabilize TS-1 a, whereas
unfavourable edge-to-face interactions might be present in
TS-1b.[18] The diastereoselective, CC bond-forming cycliza-
tion of III can then proceed via TS-2 to give the intermediate
IV. We suggest that copper coordinates to the nitrogen atom
during this step, in agreement with previous reports.[19] Finally,
in line with the positive influence of alcohols on reactivity, we
suggest that R’OH (R’= iPr, tBu) protonates intermediate IV
to give the desired product 2b and regenerate the active
copper alkoxide catalyst I.
A highly enantio- and diastereoselective copper-catalyzed
borylative cyclization constructs two adjacent stereocentres—
including a quaternary stereocentre—and delivers a range of
pyrroloquinazolinone derivatives that are currently difficult
to access. The new process exploits an inexpensive and non-
toxic copper catalyst and commercially available chiral
phosphine ligands. Selective manipulation of the products
allows access to enantiomerically enriched quinazolinones of
medicinal relevance.
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The quinazolinone motif is an important
feature in natural products and drug
candidates although enantioselective
approaches to such scaffolds remain rare.
An enantioselective Cu-catalyzed boryl-
ative cyclization delivers pyrroloquinazo-
lines, featuring quaternary stereocenters
and synthetic handles for further deriva-
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